These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8843290)

  • 1. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.
    Takenouchi T; Tabata F; Iwata Y; Hanzawa H; Sugawara M; Ohya S
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1835-42. PubMed ID: 8843290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H; Hori S; Hiramatsu K
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
    Muñoz-Bellido JL; Alonzo Manzanares M; Martínez Andrés JA; Guttiérrez Zufiaurre MN; Ortiz G; Segovia Hernández M; García-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.
    Aeschlimann JR; Dresser LD; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):335-40. PubMed ID: 9925528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus.
    Kaatz GW; Seo SM
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2650-5. PubMed ID: 8592996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.
    Nakanishi N; Yoshida S; Wakebe H; Inoue M; Yamaguchi T; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2562-7. PubMed ID: 1667255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus.
    Piddock LJ; Jin YF; Griggs DJ
    J Antimicrob Chemother; 2001 Mar; 47(3):261-70. PubMed ID: 11222558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
    Schedletzky H; Wiedemann B; Heisig P
    J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.
    Yoshida S; Kojima T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Feb; 35(2):368-70. PubMed ID: 2024969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
    J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
    Ruiz J; Sierra JM; De Anta MT; Vila J
    Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
    Tavío MM; Vila J; Ruiz J; Ruiz J; Martín-Sánchez AM; Jiménez de Anta MT
    J Antimicrob Chemother; 1999 Dec; 44(6):735-42. PubMed ID: 10590273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
    Muñoz Bellido JL; Alonso Manzanares MA; Yagüe Guirao G; Gutiérrez Zufiaurre MN; Toldos MC; Segovia Hernández M; Garcia-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
    Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
    Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.
    Kaatz GW; Seo SM; Ruble CA
    Antimicrob Agents Chemother; 1993 May; 37(5):1086-94. PubMed ID: 8517696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.